Biological
GB221
GB221 is a biological therapy with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
67%
Ph phase_3
1
33%
Phase Distribution
2
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Other(1)
Detailed Status
Completed1
Recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (66.7%)
Phase 31 (33.3%)
Trials by Status
completed133%
recruiting133%
unknown133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_1
Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1
NCT07070999
completedphase_1
Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®
NCT04905667
unknownphase_3
Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for Injection
NCT04164615
Clinical Trials (3)
Showing 3 of 3 trials
NCT07070999Phase 1
Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1
NCT04905667Phase 1
Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®
NCT04164615Phase 3
Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for Injection
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3